Circulating tumor cells and the metastatic process: the complexity of malignancy

Abstract

Despite improvements achieved in terms of early detection and therapeutic approach, metastatic breast cancer remains one of the principal worldwide causes of death. In recent years, due to the heterogeneous response of each patient to chemotherapy, clinical research highlights the need of a personalized approach. Circulating tumor cells (CTCs) represents a promising tool for this purpose. Unfortunately, even if their correlation with severity, outcome and metastatic nature of the tumor has been established, several issues, mainly concerning their characterization and isolation, need to be solved. In this review, latest knowledge on CTCs and metastatic process in breast cancer were analyzed, aiming to understand their clinical utility and validity for a prospective therapeutic scenario.

Keywords

Breast cancer / metastasis / circulating tumor cells / personalized therapy

References

[1] Fitzmaurice C,Al Lami FH,Alizadeh-Navaei R.Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study..JAMA Oncol2018;

[2] Al-Foheidi M,Ibrahim EM.Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries..Med Oncol2013;30:471

[3] Gyawali B,Honda K,Ando Y.Should low-income countries invest in breast cancer screening?.Cancer Causes Control2016;27:1341-5

[4] Lee M,Rajaram N,Yip CH.Performance of a subsidised mammographic screening programme in Malaysia, a middle-income Asian country..BMC Public Health2017;17:127 PMCID:PMC5273834

[5] Rivera-Franco MM.Delays in breast cancer detection and treatment in developing countries..Breast Cancer (Auckl)2018;12:1178223417752677 PMCID:PMC5802601

[6] Dai X,Bai Z,Liu X.Breast cancer intrinsic subtype classification, clinical use and future trends..Am J Cancer Res2015;5:2929-43 PMCID:PMC4656721

[7] Lammert J,Kiechle M.Modifiable lifestyle factors: opportunities for (hereditary) breast cancer prevention - a narrative review..Breast Care (Basel)2018;13:109-14 PMCID:PMC5981672

[8] Turkoz FP,Petekkaya I,Kertmen N.Association between common risk factors and molecular subtypes in breast cancer patients..Breast2013;22:344-50

[9] Li J,Su K.Clinicopathological classification and traditional prognostic indicators of breast cancer..Int J Clin Exp Pathol2015;8:8500-5 PMCID:PMC4555752

[10] Hammond ME.ASCO-CAP guidelines for breast predictive factor testing: an update..Appl Immunohistochem Mol Morphol2011;19:499-500

[11] Advani PP,Perez EA.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy..Biomark Med2015;9:35-49

[12] Bandyopadhyay S,Ali-Fehmi R.Breast carcinoma: updates in molecular profiling 2018..Clin Lab Med2018;38:401-20

[13] Perou CM,Eisen MB,Jeffrey SS.Molecular portraits of human breast tumours..Nature2000;406:747-52

[14] Gusterson B.Basal-like breast cancers: from pathology to biology and back again..Stem Cell Reports2018;10:1676-86 PMCID:PMC6117459

[15] Iancu G,Iancu RC.“Triple positive” breast cancer - a novel category?.Rom J Morphol Embryol2017;58:21-6

[16] Fan C,Wessels L,Nuyten DS.Concordance among gene-expression-based predictors for breast cancer..N Engl J Med2006;355:560-9

[17] Li Z,Lu W,Wang J.Immunotherapeutic interventions of triple negative breast cancer..J Transl Med2018;16:147 PMCID:PMC5977468

[18] Jitariu AA,Ribatti D.Triple negative breast cancer: the kiss of death..Oncotarget2017;8:46652-62 PMCID:PMC5542300

[19] Yousefi M,Salmaninejad A,Shahryari A.Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis..Cell Oncol (Dordr)2018;41:123-40

[20] Wu SG,Tang LY,Zhang WW.The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis..Tumour Biol2017;39:1010428317705082

[21] Appierto V,Reduzzi C,Cappelletti V.How to study and overcome tumor heterogeneity with circulating biomarkers: the breast cancer case..Semin Cancer Biol2017;44:106-16

[22] Masuda T,Iguchi T,Eguchi H.Clinical and biological significance of circulating tumor cells in cancer..Mol Oncol2016;10:408-17 PMCID:PMC5528976

[23] Lianidou ES,Markou A.Circulating tumor cells as promising novel biomarkers in solid cancers..Crit Rev Clin Lab Sci2014;51:160-71

[24] Hiller JG,Poulogiannis G,Sloan EK.Perioperative events influence cancer recurrence risk after surgery..Nat Rev Clin Oncol2018;15:205-18

[25] Bidard FC,Fehm T,Gisbert-Criado R.Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data..Lancet Oncol2014;15:406-14

[26] Bidard FC,Riethdorf S,Esserman LJ.Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis..J Natl Cancer Inst2018;110:560-7

[27] Cabel L,Gortais H,Coussy F.Circulating tumor cells: clinical validity and utility..Int J Clin Oncol2017;22:421-30

[28] Tungsukruthai S,Chanvorachote P.Molecular mechanisms of breast cancer metastasis and potential anti-metastatic compounds..Anticancer Res2018;38:2607-18

[29] Micalizzi DS,Haber DA.A conduit to metastasis: circulating tumor cell biology..Genes Dev2017;31:1827-40 PMCID:PMC5695084

[30] Scully OJ,Yip G.Breast cancer metastasis..Cancer Genomics Proteomics2012;9:311-20

[31] Dasgupta A,Ghajar CM.Circulating and disseminated tumor cells: harbingers or initiators of metastasis?.Mol Oncol2017;11:40-61 PMCID:PMC5423226

[32] Krawczyk N,Banys M,Ruckhaeberle E.Expression of stem cell and epithelial-mesenchymal transition markers in circulating tumor cells of breast cancer patients..Biomed Res Int2014;2014:415721 PMCID:PMC4034492

[33] Goodman CR,Friedl TWP,Lato K.Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer..JAMA Oncol2018;4:e180163 PMCID:PMC6143053

[34] Giuliano M,Lo HC,De Placido S.Perspective on circulating tumor cell clusters: why it takes a village to metastasize..Cancer Res2018;78:845-52

[35] Rossi G,Rademaker AW,Strickland KS.Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer..Clin Cancer Res2018;24:560-8

[36] Wang C,Chervoneva I,Ye Z.Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer..Breast Cancer Res Treat2017;161:83-94

[37] Mu Z,Uzan G,Ye Z.Detection and characterization of circulating tumor associated cells in metastatic breast cancer..Int J Mol Sci2016;17:E1665 PMCID:PMC5085698

[38] Dawood S.Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?.Pharmacogenomics2015;16:669-72

[39] Giuliano M,Jackson S,Mego M.Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination..Breast Cancer Res2014;16:440 PMCID:PMC4303121

[40] Cristofanilli M.Circulating tumour cells: telling the truth about metastasis..Lancet Oncol2014;15:365-6

[41] Jiang ZF,Shao ZM,Song EW.Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial..Ann Oncol2013;24:2766-72

[42] Cristofanilli M.Circulating tumor DNA to monitor metastatic breast cancer..N Engl J Med2013;369:93

[43] Dong X,Cristofanilli M.Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis..Chin J Cancer Res2012;24:388-98 PMCID:PMC3551332

[44] Giuliano AE,Hortobagyi GN.Eighth Edition of the AJCC cancer staging manual: breast cancer..Ann Surg Oncol2018;25:1783-5

[45] Stone RC,Ojeh N,Liu S.Epithelial-mesenchymal transition in tissue repair and fibrosis..Cell Tissue Res2016;365:495-506 PMCID:PMC5011038

[46] Forte E,Rosa P,Pagano F.EMT/MET at the crossroad of stemness, regeneration and oncogenesis: the Ying-Yang equilibrium recapitulated in cell spheroids..Cancers (Basel)2017;9:E98 PMCID:PMC5575601

[47] Roche J.The Epithelial-to-mesenchymal transition in cancer..Cancers (Basel)2018;10: PMCID:PMC5836084

[48] Kalluri R.The basics of epithelial-mesenchymal transition..J Clin Invest2009;119:1420-8 PMCID:PMC2689101

[49] Gos M,Przybyszewska M.Epithelial-mesenchymal transition in cancer progression..Postepy Biochem2009;55:121-8

[50] Tiwari N,Tatari M.EMT as the ultimate survival mechanism of cancer cells..Semin Cancer Biol2012;22:194-207

[51] Lowes LE.Circulating tumor cells and implications of the epithelial-to-mesenchymal transition..Adv Clin Chem2018;83:121-81

[52] Xu J,Derynck R.TGF-beta-induced epithelial to mesenchymal transition..Cell Res2009;19:156-72 PMCID:PMC4720263

[53] Derynck R,Saeteurn KY.Signaling pathway cooperation in TGF-β-induced epithelial-mesenchymal transition..Curr Opin Cell Biol2014;31:56-66 PMCID:PMC4657734

[54] Petrova YI,Gumbiner BM.Roles for E-cadherin cell surface regulation in cancer..Mol Biol Cell2016;27:3233-44 PMCID:PMC5170857

[55] Phillips S.SLUG: critical regulator of epithelial cell identity in breast development and cancer..Cell Adh Migr2014;8:578-87 PMCID:PMC4594335

[56] Micalizzi DS,Ford HL.Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression..J Mammary Gland Biol Neoplasia2010;15:117-34 PMCID:PMC2886089

[57] Sánchez-Tilló E,de Barrios O,Fanlo L.EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness..Cell Mol Life Sci2012;69:3429-56

[58] Godde NJ,Elsum IA.Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions..J Mammary Gland Biol Neoplasia2010;15:149-68

[59] Gloushankova NA,Zhitnyak IY.Cadherin-mediated cell-cell interactions in normal and cancer cells..Tissue Barriers2017;5:e1356900 PMCID:PMC5571778

[60] Lustberg MB,Miller B,Deighan C.Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients..Breast Cancer Res2014;16:R23 PMCID:PMC4053256

[61] Bredemeier M,Mach P,Sjöback R.Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer..Clin Chem2017;63:1585-93

[62] Ušiaková Z,Pintérová D,Valchář J.Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success..In Vivo2014;28:605-14

[63] Yan WT,Chen Q,Cui YH.Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis..Sci Rep2017;7:43464 PMCID:PMC5364512

[64] Hensler M,Becht E,Strnad P.Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients..Oncoimmunology2016;5:e1102827 PMCID:PMC4839342

[65] Markiewicz A,Wełnicka-Jaśkiewicz M,Skokowski J.Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential..PLoS One2014;9:e93901 PMCID:PMC3977989

[66] Lasa A,Alonso C,Cornet M.Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells..PLoS One2013;8:e74079 PMCID:PMC3776801

[67] Molloy TJ,Helgason HH,Hauptmann M.A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer..Br J Cancer2011;104:1913-9 PMCID:PMC3111197

[68] Obermayr E,Tea MK,Krainer M.Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients..BMC Cancer2010;10:666 PMCID:PMC3013085

[69] Christiansen JJ.Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis..Cancer Res2006;66:8319-26

[70] Fischer KR,Lee S,Li F.Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance..Nature2015;527:472-6 PMCID:PMC4662610

[71] Bhatia S,Toh AKL,Thompson EW.Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring..Biochem J2017;474:3269-306

[72] Barriere G,Gallerani G,Zoli W.Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations..Ann Transl Med2014;2:109 PMCID:PMC4245517

[73] Francart ME,Vanwynsberghe AM,Bourcy M.Epithelial-mesenchymal plasticity and circulating tumor cells: travel companions to metastases..Dev Dyn2018;247:432-50

[74] Yang J.Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis..Dev Cell2008;14:818-29

[75] Schmitt D,Tan M.Determination of breast cancer cell migratory ability..Methods Mol Biol2016;1406:171-80

[76] Pandya P,Sanz-Moreno V.Modes of invasion during tumour dissemination..Mol Oncol2017;11:5-27 PMCID:PMC5423224

[77] Te Boekhorst V.Plasticity of cancer cell invasion-mechanisms and implications for therapy..Adv Cancer Res2016;132:209-64

[78] Jie XX,Xu CJ.Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications..Oncotarget2017;8:81558-71 PMCID:PMC5655309

[79] Tan EJ,Moustakas A.Reprogramming during epithelial to mesenchymal transition under the control of TGFβ..Cell Adh Migr2015;9:233-46 PMCID:PMC4594534

[80] Banyard J.The role of EMT and MET in cancer dissemination..Connect Tissue Res2015;56:403-13 PMCID:PMC4780319

[81] van Zijl F,Mikulits W.Initial steps of metastasis: cell invasion and endothelial transmigration..Mutat Res2011;728:23-34 PMCID:PMC4028085

[82] Lintz M,Reinhart-King CA.The mechanics of single cell and collective migration of tumor cells..J Biomech Eng2017;139: PMCID:PMC5395914

[83] Gkretsi V.Cell Adhesion and matrix stiffness: coordinating cancer cell invasion and metastasis..Front Oncol2018;8:145 PMCID:PMC5945811

[84] Carlini MJ,Puricelli L.Cross-talk between tumor cells and the microenvironment at the metastatic niche..Curr Pharm Biotechnol2011;12:1900-8

[85] Scarpa E.Collective cell migration in development..J Cell Biol2016;212:143-55 PMCID:PMC4738384

[86] Friedl P.Collective cell migration in morphogenesis, regeneration and cancer..Nat Rev Mol Cell Biol2009;10:445-57

[87] Laser-Azogui A,Israeli S,Tsarfaty I.Met-induced membrane blebbing leads to amoeboid cell motility and invasion..Oncogene2014;33:1788-98

[88] Khajah MA.Involvement of membrane blebbing in immunological disorders and cancer..Med Princ Pract.2016;25 Suppl 2:18-27 PMCID:PMC5588526

[89] Sabeh F,Weiss SJ.Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited..J Cell Biol2009;185:11-9 PMCID:PMC2700505

[90] Pinner S.Imaging amoeboid cancer cell motility in vivo..J Microsc2008;231:441-5

[91] Furge KA,Vande Woude GF.Met receptor tyrosine kinase: enhanced signaling through adapter proteins..Oncogene2000;19:5582-9

[92] Paduch R.The role of lymphangiogenesis and angiogenesis in tumor metastasis..Cell Oncol (Dordr)2016;39:397-410 PMCID:PMC5052283

[93] Karlsson MC,Welin J.Epithelial-mesenchymal transition in cancer metastasis through the lymphatic system..Mol Oncol2017;11:781-91 PMCID:PMC5496496

[94] Farnsworth RH,Stacker SA.The evolving role of lymphatics in cancer metastasis..Curr Opin Immunol2018;53:64-73

[95] Karaman S.Mechanisms of lymphatic metastasis..J Clin Invest2014;124:922-8 PMCID:PMC3938272

[96] Karpanen T,Karkkainen MJ,Ylä-Herttuala S.Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth..Cancer Res2001;61:1786-90

[97] Yazawa Y.Bilateral endolymphatic hydrops in Menière’s disease: review of temporal bone autopsies..Ann Otol Rhinol Laryngol1990;99:524-8

[98] Vaahtomeri K,Mäkinen T.Lymphangiogenesis guidance by paracrine and pericellular factors..Genes Dev2017;31:1615-34 PMCID:PMC5647933

[99] Ji RC.Lymph nodes and cancer metastasis: new perspectives on the role of intranodal lymphatic sinuses..Int J Mol Sci2016;18: PMCID:PMC5297686

[100] Ran S,Hall K.Lymphangiogenesis and lymphatic metastasis in breast cancer..Pathophysiology2010;17:229-51 PMCID:PMC2891887

[101] Nakamura Y,Tsujimoto M,Nakahara M.Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer..Breast Cancer Res Treat2005;91:125-32

[102] Domschke C,Stefanovic S,Heil J.Cellular immune responses and immune escape mechanisms in breast cancer: determinants of immunotherapy..Breast Care (Basel)2016;11:102-7 PMCID:PMC4881254

[103] Terry S,Ortiz-Cuaran S,Saintigny P.New insights into the role of EMT in tumor immune escape..Mol Oncol2017;11:824-46 PMCID:PMC5496499

[104] Wang M,Song Y,Wang Y.Mechanism of immune evasion in breast cancer..Onco Targets Ther2017;10:1561-73 PMCID:PMC5359138

[105] Francisco LM,Brown KE,Freeman GJ.PD-L1 regulates the development, maintenance, and function of induced regulatory T cells..J Exp Med2009;206:3015-29 PMCID:PMC2806460

[106] Chen L,Goswami S,Ahn YH.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression..Nat Commun2014;5:5241 PMCID:PMC4212319

[107] Zhang P,Ma L.ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance..Cell Cycle2015;14:481-7 PMCID:PMC4614883

[108] Chen J,Jin L.Regulation of PD-L1: a novel role of pro-survival signalling in cancer..Ann Oncol2016;27:409-16

[109] Schütz F,Mayer L,Domschke C.PD-1/PD-L1 pathway in breast cancer..Oncol Res Treat2017;40:294-7

[110] Sabatier R,Mamessier E,Chaffanet M.Prognostic and predictive value of PDL1 expression in breast cancer..Oncotarget2015;6:5449-64 PMCID:PMC4467160

[111] Mazel M,Pantel K,Topart D.Frequent expression of PD-L1 on circulating breast cancer cells..Mol Oncol2015;9:1773-82 PMCID:PMC5528721

[112] Bębenek M,Koźlak J.Prognostic value of the Fas/Fas ligand system in breast cancer..Contemp Oncol (Pozn)2013;17:120-2 PMCID:PMC3685366

[113] Kim R,Tanabe K,Toge T.The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy..Cancer2004;100:2281-91

[114] Paget S.The distribution of secondary growths in cancer of the breast. 1889..Cancer Metastasis Rev1989;8:98-101

[115] de Groot AE,Brown JS,Amend SR.Revisiting Seed and Soil: examining the primary tumor and cancer cell foraging in metastasis..Mol Cancer Res2017;15:361-70 PMCID:PMC5380470

[116] Amelot A,Mazeron JJ,Cornu P.Timeline metastatic progression: in the wake of the « seed and soil » theory..Med Oncol2017;34:185

[117] Psaila B.The metastatic niche: adapting the foreign soil..Nat Rev Cancer2009;9:285-93 PMCID:PMC3682494

[118] Chikina AS.The cellular mechanisms and regulation of metastasis formation..Mol Biol (Mosk)2014;48:195-213

[119] Peinado H,Matei IR,Hoshino A.Pre-metastatic niches: organ-specific homes for metastases..Nat Rev Cancer2017;17:302-17

[120] Chin AR.Cancer tills the premetastatic field: mechanistic basis and clinical implications..Clin Cancer Res2016;22:3725-33 PMCID:PMC4970897

[121] Peinado H,Lyden D.The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts..Semin Cancer Biol2011;21:139-46

[122] Liu ZJ,Zhang HF.Hypoxia-inducible factor 1 and breast cancer metastasis..J Zhejiang Univ Sci B2015;16:32-43 PMCID:PMC4288942

[123] Inácio Pinto N,Oyama LM,Alcântara PS.Cancer as a proinflammatory environment: metastasis and cachexia..Mediators Inflamm2015;2015:791060 PMCID:PMC4609868

[124] Xie HY,Li DQ.Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis..Chin J Cancer2017;36:36 PMCID:PMC5372254

[125] Cox TR,Schoof EM,Høye AM.The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase..Nature2015;522:106-10 PMCID:PMC4961239

[126] Barkan D,Chambers AF.Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth..Eur J Cancer2010;46:1181-8 PMCID:PMC2856784

[127] Cox TR,Erler JT.Lysyl oxidase, a targetable secreted molecule involved in cancer metastasis..Cancer Res2016;76:188-92

[128] Erler JT,Cox TR,Bird D.Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche..Cancer Cell2009;15:35-44 PMCID:PMC3050620

[129] Cox TR,Baker AM,Ho MW.LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis..Cancer Res2013;73:1721-32 PMCID:PMC3672851

[130] Barker HE,Lang G.Tumor-secreted LOXL2 activates fibroblasts through FAK signaling..Mol Cancer Res2013;11:1425-36 PMCID:PMC3833835

[131] Endo M,Kadomatsu T,Kuroda H.Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis..Cancer Res2012;72:1784-94

[132] García-Román J.Vascular permeability changes involved in tumor metastasis..Cancer Lett2013;335:259-69

[133] Saharinen P,Pulkki K,Alitalo K.VEGF and angiopoietin signaling in tumor angiogenesis and metastasis..Trends Mol Med2011;17:347-62

[134] Heymann D.Circulating tumor cells: the importance of single cell analysis..Adv Exp Med Biol2018;1068:45-58

[135] Desitter I,Benali-Furet N,Jänne PA.A new device for rapid isolation by size and characterization of rare circulating tumor cells..Anticancer Res2011;31:427-41

[136] Li Y,Bai F.Molecular characterization of circulating tumor cells-from bench to bedside..Semin Cell Dev Biol2018;75:88-97

[137] Grover PK,Price TJ,Hardingham JE.Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research..Ann Oncol2014;25:1506-16

[138] Lee JS,Park JW.Circulating tumor cells in breast cancer: applications in personalized medicine..Breast Cancer Res Treat2016;160:411-24

[139] Königsberg R,Bises G,Gneist M.Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients..Acta Oncol2011;50:700-10

[140] Campton DE,Nordberg JJ,Clein AC.High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining..BMC Cancer2015;15:360 PMCID:PMC4430903

[141] Hillig T,Nygaard AB,Nejlund S.In vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods..Tumour Biol2015;36:4597-601 PMCID:PMC4529454

[142] Adams DL,Haudenschild C,Charpentier M.Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(^®) CTC test..Cytometry A2015;87:137-44

[143] Vona G,Louha M,Romana S.Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells..Am J Pathol2000;156:57-63 PMCID:PMC1868645

[144] Zhou MD,Williams AJ,Schrand B.Separable bilayer microfiltration device for viable label-free enrichment of circulating tumour cells..Sci Rep2014;4:7392 PMCID:PMC4260227

[145] Ozkumur E,Ciciliano JC,Miyamoto DT.Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells..Sci Transl Med2013;5:179ra47 PMCID:PMC3760275

[146] Stott SL,Tsukrov DI,Miyamoto DT.Isolation of circulating tumor cells using a microvortex-generating herringbone-chip..Proc Natl Acad Sci U S A2010;107:18392-7 PMCID:PMC2972993

[147] Harb W,Tran T,Keys D.Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay..Transl Oncol2013;6:528-38 PMCID:PMC3799195

[148] Kalinsky K,Xu X,Wong KL.Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients..Clin Transl Oncol2015;17:539-46 PMCID:PMC4497875

[149] Xu L,Imrali A,Mutsvangwa K.Optimization and evaluation of a novel size based circulating tumor cell isolation system..PLoS One2015;10:e0138032 PMCID:PMC4580600

[150] Sollier E,Che J,O’Byrne S.Size-selective collection of circulating tumor cells using Vortex technology..Lab Chip2014;14:63-77

[151] Khoo BL,Tan DS,Irwin D.Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells..PLoS One2014;9:e99409 PMCID:PMC4085042

[152] Gerges N,Jabado N.New technologies for the detection of circulating tumour cells..Br Med Bull2010;94:49-64

[153] Cristofanilli M,Ellis MJ,Matera J.Circulating tumor cells, disease progression, and survival in metastatic breast cancer..N Engl J Med2004;351:781-91

[154] Talasaz AH,Huber DE,Roh KH.Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device..Proc Natl Acad Sci U S A2009;106:3970-5 PMCID:PMC2645911

[155] Chinen LT,Rocha BM,Abdallah EA.Cytokeratin-based CTC counting unrelated to clinical follow up..J Thorac Dis2013;5:593-9 PMCID:PMC3815714

[156] Somlo G,Frankel P,Liu X.Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology..Breast Cancer Res Treat2011;128:155-63 PMCID:PMC3543871

[157] Andreopoulou E,Rangel KM,Hsu L.Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system..Int J Cancer2012;130:1590-7

[158] López-Riquelme N,Villar-Permuy F,Castillejo A.Imaging cytometry for counting circulating tumor cells: comparative analysis of the CellSearch vs ImageStream systems..APMIS2013;121:1139-43

[159] Magbanua MJ.Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling..Methods2013;64:114-8

[160] Magbanua MJ,Roy R,Scott JH.Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients..Cancer Res2013;73:30-40 PMCID:PMC4085329

[161] Morris RJ.Circulating tumor cells: quintessential precision oncology presenting challenges for biology..NPJ Precis Oncol2017;1:16 PMCID:PMC5871796

[162] Wallwiener M,Hartkopf AD,Nees J.Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients..BMC Cancer2014;14:512 PMCID:PMC4226959

[163] Eisenhauer EA,Bogaerts J,Sargent D.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)..Eur J Cancer2009;45:228-47

[164] Raimondi C,Naso G,Petracca A.Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients..Breast Cancer Res Treat2011;130:449-55

[165] Giordano A,Anfossi S,Mego M.Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer..Mol Cancer Ther2012;11:2526-34 PMCID:PMC3500676

[166] Mego M,Dawood S,Valero V.Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells..Int J Cancer2011;129:417-23

[167] Satelli A,Brownlee Z,Zhou S.EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression..Oncotarget2017;8:49329-37 PMCID:PMC5564771

[168] Serrano MJ,Alvarez-Cubero MJ,Sanchez-Rovira P.EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer..Oncotarget2014;5:7486-97 PMCID:PMC4202138

[169] Duffy MJ,Crown J.Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA..Tumour Biol2018;40:1010428318776169

[170] Austin RG,Wu M,Zhang T.Clinical utility of non-EpCAM based circulating tumor cell assays..Adv Drug Deliv Rev2018;125:132-42

[171] Khatami F,Sanaei M,Tavangar SM.The potential of circulating tumor cells in personalized management of breast cancer: a systematic review..Acta Med Iran2017;55:175-93

[172] Shao Y,He Y,Liu H.Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer..PLoS One2015;10:e0133830 PMCID:PMC4514648

[173] Gion M,Barioli P,Capitanio G.Tissue polypeptide antigen and tissue polypeptide specific antigen in primary breast cancer. Evaluation in serum and tumour tissue..Eur J Clin Chem Clin Biochem1994;32:779-87

[174] Tchou J,Li YR,Ky B.Monitoring serum HER2 levels in breast cancer patients..Springerplus2015;4:237 PMCID:PMC4456592

[175] Mokuyasu S,Seto T,Tokuda Y.A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry..Rinsho Byori2012;60:612-20

[176] Fujimoto Y,Nishimukai A,Kira A.High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy..J Surg Oncol2018;

[177] Kucera R,Fiala O,Treska V.The role of TPS and TPA in the diagnostics of distant metastases..Anticancer Res2016;36:773-7

[178] Tang SS.Biomarkers in the diagnosis of primary and recurrent breast cancer..Biomark Med2012;6:567-85

[179] Mariani L,Michilin S.Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences..Biomarkers2009;14:130-6

[180] Smerage JB,Hortobagyi GN,Leyland-Jones B.Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500..J Clin Oncol2014;32:3483-9 PMCID:PMC4209100

[181] Larsson AM,Bendahl PO,Loman N.Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial..Breast Cancer Res2018;20:48 PMCID:PMC5994056

[182] Lu YJ,Wang X,Zhu YW.The significant prognostic value of circulating tumor cells in triple-negative breast cancer: a meta-analysis..Oncotarget2016;7:37361-9 PMCID:PMC5095082

[183] Kang Y.Tumor cell dissemination: emerging biological insights from animal models and cancer patients..Cancer Cell2013;23:573-81 PMCID:PMC3667710

[184] Van Poznak C,Bast RC,Goetz MP.Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: american society of clinical oncology clinical practice guideline..J Clin Oncol2015;33:2695-704 PMCID:PMC5478102

[185] Ellsworth RE,Shriver CD,Ellsworth DL.Molecular heterogeneity in breast cancer: State of the science and implications for patient care..Semin Cell Dev Biol2017;64:65-72

[186] Fehm T,Aktas B,Schneeweiss A.HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial..Breast Cancer Res Treat2010;124:403-12

[187] Georgoulias V,Agelaki S,Apostolaki S.Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study..Ann Oncol2012;23:1744-50

[188] Paoletti C,Thomas DG,Kidwell KM.Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer..Clin Cancer Res2015;21:2487-98 PMCID:PMC5516625

[189] Arteaga CL.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics..Cancer Cell2014;25:282-303 PMCID:PMC4018830

[190] Riethdorf S,Zhang L,Loibl S.Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial..Clin Cancer Res2010;16:2634-45

[191] Bardelli A.Liquid biopsies, what we do not know (yet)..Cancer Cell2017;31:172-9